Universal Beteiligungs und Servicegesellschaft mbH Takes $1.60 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has purchased 54,651 shares of Agios Pharmaceuticals, valued at approximately $1,601,000, representing about 0.09% ownership of the company.
• Agios Pharmaceuticals shares have decreased by 6.0% to $35.00, with significant trading volume of 2,351,119 shares on a day when the average is around 723,031.
• Research analysts have mixed opinions on AGIO, with one sell rating, two hold ratings, and six buy ratings, indicating a consensus rating of "Moderate Buy" with an average price target of $56.33.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 54,651 shares of the biopharmaceutical company's stock, valued at approximately $1,601,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.09% of Agios Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Summit Investment Advisors Inc. lifted its holdings in Agios Pharmaceuticals by 7.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after purchasing an additional 394 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after purchasing an additional 582 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Agios Pharmaceuticals by 1.2% during the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after purchasing an additional 708 shares in the last quarter. Gallagher Fiduciary Advisors LLC lifted its stake in shares of Agios Pharmaceuticals by 7.6% in the fourth quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company's stock worth $365,000 after buying an additional 788 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Agios Pharmaceuticals by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock worth $815,000 after buying an additional 795 shares in the last quarter.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,770 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the transaction, the insider owned 26,122 shares in the company, valued at $876,131.88. The trade was a 9.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sarah Gheuens sold 11,914 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total transaction of $452,612.86. Following the completion of the transaction, the insider owned 61,271 shares of the company's stock, valued at $2,327,685.29. This represents a 16.28% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,363 shares of company stock valued at $1,619,654. 4.30% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Stock Up 0.7%

Shares of AGIO traded up $0.24 during trading on Tuesday, reaching $36.40. 437,290 shares of the company traded hands, compared to its average volume of 715,271. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The stock has a market cap of $2.11 billion, a PE ratio of 3.30 and a beta of 0.80. The stock has a 50-day simple moving average of $35.81 and a 200-day simple moving average of $32.60.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a research note on Monday, July 28th. Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Bank of America cut their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.